- Home
- GLAD vs DNTH Comparison
GLAD vs DNTH Comparison
Compare GLAD & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- DNTH
- Stock Information
- Founded
- GLAD 2001
- DNTH 2015
- Country
- GLAD United States
- DNTH United States
- Employees
- GLAD N/A
- DNTH N/A
- Industry
- GLAD Finance/Investors Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- GLAD Finance
- DNTH Health Care
- Exchange
- GLAD Nasdaq
- DNTH Nasdaq
- Market Cap
- GLAD 571.4M
- DNTH 657.0M
- IPO Year
- GLAD N/A
- DNTH N/A
- Fundamental
- Price
- GLAD $26.41
- DNTH $17.53
- Analyst Decision
- GLAD Hold
- DNTH Strong Buy
- Analyst Count
- GLAD 1
- DNTH 8
- Target Price
- GLAD $23.00
- DNTH $53.00
- AVG Volume (30 Days)
- GLAD 100.6K
- DNTH 255.5K
- Earning Date
- GLAD 05-06-2025
- DNTH 05-12-2025
- Dividend Yield
- GLAD 8.99%
- DNTH N/A
- EPS Growth
- GLAD 17.67
- DNTH N/A
- EPS
- GLAD 3.93
- DNTH N/A
- Revenue
- GLAD $92,932,000.00
- DNTH $6,524,000.00
- Revenue This Year
- GLAD N/A
- DNTH N/A
- Revenue Next Year
- GLAD $14.02
- DNTH N/A
- P/E Ratio
- GLAD $6.74
- DNTH N/A
- Revenue Growth
- GLAD N/A
- DNTH 102.36
- 52 Week Low
- GLAD $21.40
- DNTH $13.37
- 52 Week High
- GLAD $30.43
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- GLAD 53.40
- DNTH 37.32
- Support Level
- GLAD $25.40
- DNTH $16.91
- Resistance Level
- GLAD $26.81
- DNTH $18.45
- Average True Range (ATR)
- GLAD 0.62
- DNTH 1.14
- MACD
- GLAD 0.02
- DNTH -0.20
- Stochastic Oscillator
- GLAD 50.25
- DNTH 17.97
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.